The identification of YBX1-targeting compounds through virtual screening and MD simulations offers a rational framework for the development of targeted therapies, advancing the translational potential of YBX1 as a diagnostic and therapeutic target in IPF. This evidence concerns the gene YBX1 and idiopathic pulmonary fibrosis.